Sensory testing might not be perfect – but it is the best biomarker for pain phenotypes we have right now-Reference-Cited by-同舟云学术

Sensory testing might not be perfect – but it is the best biomarker for pain phenotypes we have right now

Published:2022-09-22 Issue:4 Volume:22 Page:673-675
ISSN:1877-8860
Container-title:Scandinavian Journal of Pain
language:en
Short-container-title:

Author:

Vollert Jan¹²³⁴

Affiliation:

1. Pain Research, Department of Surgery and Cancer , Imperial College London , London , UK

2. Division of Neurological Pain Research and Therapy, Department of Neurology , University Hospital of Schleswig-Holstein , Campus Kiel , Kiel , Germany

3. Department of Anaesthesiology, Intensive Care and Pain Medicine , University Hospital Muenster , Muenster , Germany

4. Neurophysiology , Mannheim Center of Translational Neuroscience (MCTN), Medical Faculty Mannheim, Heidelberg University , Heidelberg , Germany

Abstract

Abstract Currently available treatments for neuropathic pain fail in roughly half of the patients – and it is impossible to predict which treatments will help patients. Stratification of neuropathic pain patients is needed, and sensory profiling has so far been the most promising approach: it has been shown to be responsive to treatment, linked to potential mechanisms, and, most importantly, predictive of treatment success. Despite a number of limitations, it is the currently most promising stratification tool and should be refined rather than disregarded.

Publisher

Walter de Gruyter GmbH

Subject

Anesthesiology and Pain Medicine,Neurology (clinical)

Link

https://www.degruyter.com/document/doi/10.1515/sjpain-2022-0092/pdf

Reference20 articles.

1. Rice, ASC, Smith, BH, Blyth, FM. Pain and the global burden of disease. Pain 2016;157:791–6. https://doi.org/10.1097/j.pain.0000000000000454.

2. Clauw, DJ, Häuser, W, Cohen, SP, Fitzcharles, M-A. Considering the potential for an increase in chronic pain after the COVID-19 pandemic. Pain 2020;161:1694–7. https://doi.org/10.1097/j.pain.0000000000001950.

3. Finnerup, NB, Attal, N, Haroutounian, S, McNicol, E, Baron, R, Dworkin, RH, et al.. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162–73. https://doi.org/10.1016/s1474-4422(14)70251-0.

4. Dworkin, RH, O’Connor, AB, Backonja, M, Farrar, JT, Finnerup, NB, Jensen, TS, et al.. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237–51. https://doi.org/10.1016/j.pain.2007.08.033.

5. Rolke, R, Baron, R, Maier, C, Tölle, TR, Treede, R-D, Beyer, A, et al.. Quantitative sensory testing in the German Research Network on neuropathic pain (DFNS): standardized protocol and reference values. Pain 2006;123:231–43. https://doi.org/10.1016/j.pain.2006.01.041.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving neuropathic pain treatment – by rigorous stratification from bench to bedside;Journal of Neurochemistry;2023-04-07